Revenue segments as reported by the company.

Protein Sciences

Diagnostics and Genomics

lntersegment

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Bio-Techne Corp reports steady Q3 revenue growth amidst China challenges

Bio-Techne Corp reported steady Q3 revenue growth despite challenges in China and temporary headwinds. The company is focused on driving growth in strategic platforms and expanding key franchises. Succession planning and margin improvement are key areas of focus for future growth.

Bio-Techne reports strong Q2 earnings, eyes growth in diagnostics

Bio-Techne's Q2 2023 earnings call highlighted solid performance, strategic strengths in key segments, challenges in ordering patterns, and growth opportunities in diagnostics and research.
The company's focus on innovation, cost management, and strategic investments positions it well for future growth and reaching ambitious revenue targets by FY 2026.
Despite short-term challenges in certain markets, Bio-Techne remains optimistic about its long-term growth prospects and transparent communication with investors.
With a strong financial performance, expanding product portfolio, and a focus on high-growth areas, Bio-Techne is poised for sustained success and market leadership.

Bio-Techne reports solid Q3 performance, eyes growth in key segments

Bio-Techne's Q3 performance showcased strengths in key segments like ExoDx Prostate test demand and GMP proteins, despite challenges in certain markets and OEM destocking dynamics. The company's strategic focus on expanding the Wilson Wolf franchise and driving growth in ACD and key segments like cell and gene therapy position it well for future success. Addressing challenges and capitalizing on growth opportunities will be pivotal for Bio-Techne's continued expansion and market leadership.

Bio-Techne (TECH) excels in Q4, eyes growth amid challenges

Bio-Techne (TECH) reports strong revenue growth and promising future prospects.
Strategic focus on key segments like cell and gene therapy and spatial biology.
Challenges in macroenvironment and funding uncertainties require cautious navigation.
Active M&A strategy and investments to drive growth and market dominance.

Bio-Techne reports steady Q1 growth amid industry challenges

Bio-Techne's Q1 performance showed resilience amidst industry challenges, with a focus on key growth areas and regions. While facing headwinds, the company remains cautiously optimistic about future prospects, emphasizing long-term growth opportunities and productivity measures.

Bio-Techne reports Q2 revenue growth amidst China challenges and opportunities

Bio-Techne's Q2 performance reflects revenue growth and operational efficiency, despite challenges.
Strengths lie in core businesses, Diagnostics and Genomics growth, and record consumables usage in China.
Challenges include market declines, funding constraints, and headwinds in biopharma and academic markets.
Opportunities exist in market normalization, China growth, new product releases, and M&A strategies.

Bio-Techne surpasses Q3 expectations, eyes growth in emerging markets

Bio-Techne's Q3 showcased strong financial performance, with revenue growth and margin expansion across key segments, setting the stage for continued success.
The company's focus on innovation, awards recognition, and strategic market positioning in high-growth areas like cell and gene therapy underpin its competitive strength.
While facing challenges in certain regions and production constraints, Bio-Techne's proactive approach to scaling up manufacturing and diversifying markets positions it well for future growth.
With a clear emphasis on operational efficiency, market expansion, and strategic investments, Bio-Techne is poised for sustained success and value creation for stakeholders.

Bio-Techne reports solid Q4 performance and eyes market recovery

Bio-Techne's Q4 2024 performance reflects resilience and potential for accelerated growth as markets recover in fiscal year 2025.
Strategic leadership additions, productivity initiatives, and market recovery expectations position the company for future success.
Challenges such as capacity constraints and funding environments require strategic management for sustained growth.
Opportunities lie in market recovery, margin improvement, and growth prospects across different segments for Bio-Techne in the coming year.

Bio-Techne reports solid Q1 earnings, eyes growth in biotech markets

Bio-Techne (TECH) delivered solid Q1 2025 results with organic revenue growth, strong segment performances, and a focus on sustainability and strategic partnerships.
While facing challenges in certain markets, the company's emphasis on cost containment and productivity optimization bodes well for future profitability and resilience.
With a positive outlook for growth and opportunities in key segments, Bio-Techne is poised for continued success and market leadership in the biotech industry.
Investors can be optimistic about Bio-Techne's performance, strategic initiatives, and growth prospects, supported by a strong financial foundation and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Arcturus Therapeutics

Vertex Pharmaceuticals

During this Q3 of 2023, there have been many changes to U.S. healthcare at different levels. At the state level, there were changes to gender-affirming care.

3 Biotech Stocks to Buy Before the Breakout

MINNEAPOLIS , July 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, August 8, 2023, at 8:00 a.m. CDT to review fourth quarter and fiscal 2023 financial results.

BIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 8, 2023, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2023 FINANCIAL RESULTS

MINNEAPOLIS , July 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced it has completed the acquisition of Lunaphore Technologies SA, a leading developer of fully automated spatial biology solutions. Bio-Techne and Lunaphore are combining forces to accelerate their spatial biology leadership position in translational and clinical research markets.

BIO-TECHNE COMPLETES LUNAPHORE ACQUISITION

GlaxoSmithKline

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with GSK (GSK) and Techne (TECH). But which of these two stocks is more attractive to value investors?

GSK vs. TECH: Which Stock Is the Better Value Option?

TOLOCHENAZ, Switzerland & MINNEAPOLIS--(BUSINESS WIRE)--Lunaphore Technologies SA, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it has reached an agreement to be acquired by Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. The acquisition is anticipated to close in Q3. Founded in 2014 and headquartered i.

Lunaphore to Get Acquired by Bio-Techne

MINNEAPOLIS and TOLOCHENAZ, Switzerland , June 22, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Lunaphore, Inc. Bio-Techne anticipates the acquisition to close in the first quarter of its fiscal 2024. Founded in 2014 and headquartered in Tolochenaz, Switzerland, Lunaphore is a leading developer of fully automated spatial biology solutions using precision microfluidic technology capable of revealing hyperplex proteomic and transcriptomic biomarkers in tumors and other tissues at single-cell and subcellular resolution.

BIO-TECHNE TO ACQUIRE LUNAPHORE

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either GSK (GSK) or Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?

GSK vs. TECH: Which Stock Should Value Investors Buy Now?

MINNEAPOLIS , June 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies it developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.

BIO-TECHNE SUCCESSFUL ON CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC

MINNEAPOLIS , May 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 Jefferies Healthcare Conference on Thursday, June 8, 2023, at 12:30 p.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE 2023 JEFFERIES HEALTHCARE CONFERENCE

Bio-Techne Corporation has been a long term value creator, combining organic growth with sound M&A deals. This has resulted in long-term value creation, as Bio-Techne Corporation shares have looked pricey for a long time.

Bio-Techne Corporation: Long-Term Quality, But At A Price

Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS , May 18, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a previously published prospective, randomized study of more than 1,000 patients aimed at evaluating the clinical utility of the ExoDx™ Prostate Test over a 5-year follow-up period. This study adds to the body of published evidence on the ExoDx Prostate Test.

EXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TEST

Enabling Bio-Techne's gold-standard RNAscope ISH technology with Imaging Mass Cytometry detection to accelerate multiomic interrogation of health and disease. MINNEAPOLIS , May 16, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of a RNAscope multiomic workflow for the Standard BioTools Hyperion™ Imaging System.

BIO-TECHNE COMMERCIALIZES RNASCOPE SPATIAL BIOLOGY WORKFLOW FOR THE STANDARD BIOTOOLS HYPERION IMAGING SYSTEM

MINNEAPOLIS , May 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 2:35 p.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE 2023 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

MINNEAPOLIS , May 10, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents (ASRs) for the detection of immunoglobulin kappa and lambda light chains mRNA in B-cells. Detection of B-cell clonality is useful for identification of monoclonal B-cell populations which are often associated with a malignancy.

BIO-TECHNE ANNOUNCES LAUNCH OF KAPPA AND LAMBDA RNAscope ISH PROBES AS ANALYTE SPECIFIC REAGENTS (ASRs) FOR THE DETECTION OF IMMUNOGLOBULIN KAPPA AND LAMBDA LIGHT CHAINS mRNA

Bio-Techne Corporation (NASDAQ:TECH ) Q3 2023 Earnings Conference Call May 3, 2023 9:00 AM ET Company Participants David Clair – Vice President-Investor Relations Chuck Kummeth – Chief Executive Officer Jim Hippel – Chief Financial Officer Conference Call Participants Puneet Souda – SVB Securities Jacob Johnson – Stephens Dan Arias – Stifel Dan Leonard – Credit Suisse Patrick Donnelly – Citi Catherine Schulte – Baird Justin Bowers – Deutsche Bank Alex Nowak – Craig-Hallum Operator Good day, and welcome to the Bio-Techne Corp Third Quarter Fiscal 2023 Earnings Call. All participants will be in a listen-only mode.

Bio-Techne Corporation (TECH) Q3 2023 Earnings Call Transcript

The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Techne (TECH) Q3 Earnings

Techne (TECH) came out with quarterly earnings of $0.53 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.54 per share a year ago.

Techne (TECH) Meets Q3 Earnings Estimates

MINNEAPOLIS , May 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2023. Third Quarter FY2023 Highlights Third quarter organic revenue increased by 3% (1% reported) to $294.1 million and 4% (2% reported) in the first nine months of fiscal 2023 to $835.4 million.

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2023 RESULTS

MINNEAPOLIS , May 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023, at 1:40 p.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE BofA SECURITIES 2023 HEALTH CARE CONFERENCE

BeiGene

BioMarin Pharmaceutical

Incyte

argenx

Legend Biotech

United Therapeutics

Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).

7 Biotech Stocks That Could Cure Your Portfolio Woes

MINNEAPOLIS , April 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida.

BIO-TECHNE TO SHOWCASE INNOVATIVE CANCER RESEARCH, CELL THERAPY AND MANUFACTURING TOOLS AT AACR 2023 CONFERENCE

MINNEAPOLIS , April 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 3, 2023, at 8:00 a.m. CDT to review third quarter 2023 financial results.

BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 3, 2023, TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

MINNEAPOLIS , April 5, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it that it has reached a significant milestone with more than 1,000 Ella™ automated immunoassay instruments now in the field. The achievement is a testament to the growing demand across scientific and clinical research sectors for a fast and efficient immunoassay solution capable of delivering precise, and reliable biomarker analysis.

BIO-TECHNE CELEBRATES MILESTONE WITH MORE THAN 1,000 ELLA™ INSTRUMENTS NOW IN OPERATION

MINNEAPOLIS , April 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its investment in Wilson Wolf Manufacturing. Wilson Wolf achieved the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target of $55 million, triggering Bio-Techne's initial investment in the company.

BIO-TECHNE COMPLETES INVESTMENT IN WILSON WOLF MANUFACTURING

SkyQuest's report on the Immunoassay market is a valuable analysis for individuals seeking to gain insights into the rapidly expanding industry. The report provides excellent information on trends, data, and opportunities in the market. It is written clearly and concisely, making it accessible to a wide range of audiences, from industry experts to market readers. Moreover, the report offers a comprehensive analysis of both primary and secondary market drivers, providing readers with a detailed understanding of the current market situation and future projections. In sum, SkyQuest's Immunoassay market report is a well-crafted and informative document that can benefit anyone interested in staying abreast of the developments in this industry. SkyQuest's report on the Immunoassay market is a valuable analysis for individuals seeking to gain insights into the rapidly expanding industry. The report provides excellent information on trends, data, and opportunities in the market. It is written clearly and concisely, making it accessible to a wide range of audiences, from industry experts to market readers. Moreover, the report offers a comprehensive analysis of both primary and secondary market drivers, providing readers with a detailed understanding of the current market situation and future projections. In sum, SkyQuest's Immunoassay market report is a well-crafted and informative document that can benefit anyone interested in staying abreast of the developments in this industry.

News for Bio-Techne Stock (TECH)